Drug Prices

The price of prescription drugs has skyrocketed over the past several years. These price increases are extremely troublesome throughout the health care system.

Unchecked drug price increases are not sustainable, and are a serious economic threat to the patients and communities we serve. They not only threaten patient access to drug therapies, but challenge providers’ abilities to provide the highest quality of care.

Did you know?

  • In 2015, total spending on prescription drugs surpassed $457 billion
  • Spending on drugs rose 8.5% in 2015
  • The cost of some drugs jumped as much as 3,600% over two years

Hospitals bear a heavy financial burden when the cost of drugs increases. They are not only major purchasers of drugs, but patients often end up in the hospital when they cannot afford to take their medications as prescribed.

To that end, the American Hospital Association is proud to be a member of the Campaign for Sustainable Rx Pricing -– a diverse coalition of doctors, hospitals, pharmacists, employers, health plans, seniors, patients, consumers and others coming together to find common ground and solutions.

Moving forward, the AHA is committed to working for action on policies that foster transparency, competition and value while fostering innovation.

Read on to learn more about the impact of high drug pricing on patients and hospitals.

Related Resources

AHA Center for Health Innovation Market Scan
For the second time in less than a month, the Department of Justice has approved a megamerger between leading players in the health insurance and pharmacy…
Letter
Public
AHA letter to the US Senate supporting Amendment #3787 to address ‘out-of-control cost’ of prescription drugs.
Testimony
Public
AHA statement before the Senate Committee on Health, Education, Labor and Pensions on Reducing Health Care Costs: Eliminating Excess Health Care Spending and…
Letter
Public
AHA comments on the 340B section of the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Letter
Public
AHA comments on the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Letter
Public
AHA commends MedPAC and HHS for voicing significant concerns about rising pharmaceutical costs.